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Abstract: Hypertension or high blood pressure is one of the major independent risk factors 
for cardiovascular diseases. Angiotensin-I-converting enzyme (EC 3.4.15.1; ACE) plays an 
important physiological role in regulation of blood pressure by converting angiotensin I to 
angiotensin  II,  a  potent  vasoconstrictor.  Therefore,  the  inhibition  of  ACE  activity  is  a 
major  target  in  the  prevention  of  hypertension.  Recently,  the  search  for  natural  ACE 
inhibitors  as  alternatives  to  synthetic  drugs  is  of  great  interest  to  prevent  several  side 
effects and a number of novel compounds such as bioactive peptides, chitooligosaccharide 
derivatives (COS) and phlorotannins have been derived from marine organisms as potential 
ACE  inhibitors.  These  inhibitory  derivatives  can  be  developed  as  nutraceuticals  and 
pharmaceuticals with potential to prevent hypertension. Hence, the aim of this review is to 
discuss the marine-derived ACE inhibitors and their future prospects as novel therapeutic 
drug candidates for treat hypertension. 
Keywords:  angiotensin-I-converting  enzyme  inhibitors;  antihypertensive  activity; 
bioactive peptides; chitooligosaccharides; hypertension; phlorotannins 
Abbreviations:  ACE;  angiotensin-I-converting  enzyme;  COS;  chitooligosaccharides;  
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1. Introduction 
Hypertension or high blood pressure is one of the major independent risk factors for cardiovascular 
diseases [1,2] and it is a major health issue, estimated to be affecting about 20% of the world’s adult 
population  [3].  Among  processes  related  to  hypertension,  angiotensin-I-converting  enzyme  (ACE) 
plays an important role in the regulation of blood pressure. ACE is a dipeptidyl carboxypeptidase  
(EC. 3.4.15.1) and was originally isolated from horse blood [4]. It plays a crucial role in the regulation 
of  blood  pressure  as  it  promotes  the  conversion  of  angiotensin-I  to  the  potent  vasoconstrictor 
angiotensin-II as well as inactivates the vasodilator bradykinin, which has a depressor action in the 
renin-angiotensin system. This potent vasoconstrictor is also involved in the release of a Na-retaining 
steroid, aldosterone from the adrenal cortex, which has a tendency to increase blood pressure [5]. 
Inhibition  of  ACE  is  considered  to  be  a  useful  therapeutic  approach  in  the  treatment  of 
hypertension. Therefore, in the development of drugs to control high blood pressure, ACE inhibition 
has  become  an  important  activity.  Many  studies  have  been  attempted  in  the  synthesis  of  ACE 
inhibitors  such  as  captopril,  enalapril,  alcacepril  and  lisinopril,  which  are  currently  used  in  the 
treatment of essential hypertension and heart failure in humans [6]. However, these synthetic drugs are 
believed to have certain side effects such as cough, taste disturbances, skin rashes or angioneurotic 
edema  all  of  which  might  be  intrinsically  linked  to  synthetic  ACE  inhibitors  [7].  Therefore,  the 
research and development to find safer, innovative, and economical ACE inhibitors is necessary for the 
prevention and remedy of hypertension [8,9]. Many research groups have combed for novel ACE 
inhibitors from natural products [10], microbial sources [11] and food proteins [12]. 
Marine organisms are rich sources of structurally diverse bioactive compounds.  Hence, a great 
interest has been developed nowadays to isolate bioactive compounds, which act as ACE inhibitors 
from  marine  resources  because  of  their  numerous  health  beneficial  effects.  According  to  the 
researches,  it  has  reported  that  marine-derived  bioactive  peptides,  chitooligosaccharide  derivatives 
(COS) and phlorotannins have potent ACE inhibitory activity. This review discusses the above three 
groups of marine-derived ACE inhibitors and their inhibitory properties, emphasizing their potential 
application as future pharmaceuticals to prevent hypertension. 
2. Marine-derived ACE Inhibitors and Their Antihypertensive Activity 
2.1. Bioactive peptides 
Components of proteins in food are containing sequences of bioactive peptides, which could exert a 
physiological effect in the body. These short chains of amino acids are inactive within the sequence of 
the  parent  protein,  but  can  be  released  during  gastrointestinal  digestion,  food  processing,  or 
fermentation. Marine-derived bioactive peptides have been obtained widely by enzymatic hydrolysis 
of marine proteins [13–17]. In fermented marine food sauces such as blue mussel sauce and oyster 
sauce, enzymatic hydrolysis has already been done by microorganisms, and bioactive peptides can be 
purified without further hydrolysis [18,19]. In addition, several bioactive peptides have been isolated 
from marine processing by-products or wastes [20–23]. Marine by-products generated during marine 
food processing, have low commercial value, but the detection of in vitro ACE inhibitory activity in 
these products might provide significant environmental and cost benefits. Marine-derived bioactive Mar. Drugs 2010, 8                             
 
 
1082 
peptides have been shown to possess many physiological functions, including antihypertensive or ACE 
inhibition  [24],  antioxidant  [25,26],  anticoagulant  [27,28],  and  antimicrobial  [29,30]  activities. 
Moreover, some of these bioactive peptides have identified to possess nutraceutical potentials that are 
beneficial in human health promotion [31] and recently the possible roles of food-derived bioactive 
peptides in reducing the risk of cardiovascular diseases has been shown [32]. 
Marine-derived antihypertensive peptides have shown potent ACE inhibitory activities (Table 1). 
The potency of these marine-derived peptides to inhibit ACE activity has been expressed as an IC50 
value, which is the ACE inhibitor concentration, leading to 50% inhibition of ACE activity. Moreover, 
the  inhibition  modes  of  ACE-catalyzed  hydrolysis  of  these  antihypertensive  peptides  have  been 
determined by Lineweaver-Burk plots.  
Table 1. ACE inhibitory peptides derived from marine organisms: source, enzyme used for 
hydrolysis, and IC50 value.  
Source    Enzyme  IC50  Ref. 
Blue mussel sauce  natural fermentation  19.34 µ g/mL  [19] 
Alaska pollack  pronase, flavourzyme  0.21 mg/mL  [33] 
Alaska pollack  alcalase, pronase, collagenase  2.6 µM   [34] 
Big eye tuna (muscle)  pepsin  21.6 µM   [35] 
Big eye tuna (frame)  pepsin  11.28 µM   [36] 
Shrimp  protease  0.39 µM   [37] 
Shrimp  Lactobacillus fermentum enzymes  3.37 mg/mL  [38] 
Hard clam  protamex  51 µM   [39] 
Sea cucumber  bromelain, alcalase, protease  4.5 µM   [40] 
Rotifer  alcalase  9.64 µM   [41] 
Wakame  pepsin  21 µM   [42] 
Microalga  pepsin    29.6 µM   [43] 
Yellow fin sole  α-chymotrypsin  22.3 µM   [44] 
Bonito  thermolysin  0.32 µM  [45] 
Sardine  alkaline protease  0.015 mg/mL  [46] 
Oyster  pepsin    66 µM   [47] 
Shark  protease  1.45 µM  [48] 
Anchovy fish sauce  natural fermentation  22 µM  [49] 
Sea bream  alkaline protease  0.57 mg/mL  [50] 
 
According  to  Lineweaver-Burk  plot  studies,  competitive  ACE  inhibitory  peptides  have  most 
frequently reported [18,36,40]. These inhibitors can bind to the active site to block it or to the inhibitor 
binding site that is remote from the active site to alter the enzyme conformation such that the substrate 
no longer binds to the active sites. Moreover, tryptophan, tyrosine, proline or phenylalanine at the  
C-terminal and branched-chain aliphatic amino acids at the N-terminal is suitable for peptides to act as 
competitive inhibitors by binding with ACE [51]. In addition, a non-competitive mechanism has also 
been observed in some peptides [35,52] and this means that the peptide can combine with an enzyme 
molecule to produce a dead-end complex, regardless of whether a substrate molecule is bound or not. 
The  hydrophobicity  of  the  N-terminus,  which  is  one  of  the  common  features  of  ACE  inhibitory 
peptides, may contribute to the inhibitory activity [53]. ACE inhibitory peptides are generally short Mar. Drugs 2010, 8                             
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chain peptides, often carrying polar amino acid residues like proline. Furthermore, structure-activity 
relationships  among  various  peptide  inhibitors  of  ACE  indicate  that  binding  to  ACE  is  strongly 
influenced by the C-terminal tripeptide sequence of the substrate, and it is suggested that peptides, 
which contain hydrophobic amino acids at these positions, are potent inhibitors [54]. 
Numerous  in  vivo  studies  of  marine-derived  antihypertensive  peptides  in  spontaneously 
hypertensive rats have shown potent ACE inhibition activity [35,36,40,50] and their systolic blood 
pressure has reduced significantly after oral administration of peptides. According to Lee et al. [36], a 
single oral administration (10 mg/kg of body weight) of peptide has shown a strong suppressive effect 
on systolic blood pressure of spontaneously hypertensive rats and this antihypertensive activity was 
similar with captopril, a commercial antihypertensive drug. Furthermore, they have reported that no 
side effect observed on rats after administration of antihypertensive peptide. In addition, these marine 
bioactive  peptides  exhibit  antihypertensive  activity  in  vivo  than  in  vitro.  The  exact  mechanisms 
underlying this phenomenon have not yet been identified. However, it was suggested that bioactive 
peptides have higher tissue affinities and are subject to a slower elimination than captopril [45]. The 
antihypertensive peptide isolated from bonito fish hydrolysate product, has found to be hydrolyzed by 
ACE to  produce  a  smaller  peptide  than  the  initial one, which had 8-fold ACE inhibitory activity 
compared with the initial peptide [45]. 
Therefore, marine-derived bioactive peptides have a potential in use as functional ingredients in 
nutraceuticals  and  pharmaceuticals  due  to  their  effectiveness  in  both  prevention  and  treatment  of 
hypertension in addition to the nutritive value. Some antihypertensive synthetic commercial drugs are 
known to produce side effects such as an abnormal elevation of the blood pressure after administration. 
However, marine-derived bioactive peptides are well tolerated by the body, are not expected to exert 
any  harmful side effects.  In addition, cost effective and safe drugs can be produced from marine 
bioactive  peptides,  but  further  studies  are  needed  with  clinical  trials  for  these  marine-derived 
antihypertensive peptides. 
2.2. Chitooligosaccharide derivatives (COS) 
Chitin  is  the  second  most  abundant  biopolymer  on  earth  after  cellulose  and  one  of  the  most 
abundant polysaccharide [55]. It is a glycan of β (1→4)-linked N-acetylglucosamine units and it is 
widely distributed in crustaceans and insects as the protective exo-skeleton and cell walls of most 
fungi.  Chitin  is  usually  prepared  from  the  shells  of  crabs  and  shrimps.  Chitosan,  a  partially 
deacetylated polymer of N-acetylglucosamine, is prepared by alkaline deacetylation of chitin [56]. 
Chitooligosaccharides (COS) are chitosan derivatives (polycationic polymers comprised principally of 
glucosamine units) and can be generated via either chemical or enzymatic hydrolysis of chitosan [57–59]. 
Recently,  COS  have  been  the  subject  of  increased  attention  in  terms  of  their  pharmaceutical  and 
medicinal applications [60], due to their missing toxicity and high solubility as well as their positive 
physiological  effects  such  as  ACE  enzyme  inhibition  [61],  antioxidant  [62],  antimicrobial  [63], 
anticancer [64,65], immuno-stimulant [66], antidiabetic [67], hypocholesterolemic [68], hypoglycemic [69], 
anti-Alzheimer’s [70], anticoagulant [71] properties and adipogenesis inhibition [72]. 
Researches on chitosan and its derivative oligomers have identified their potential to inhibit ACE 
activity. Even though enough studies have not been carried out, it is presumed that COS may have Mar. Drugs 2010, 8                             
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desirable  properties  to  inhibit  ACE  activity.  Recently,  marine-derived  chitooligosaccharide  (COS) 
derivatives such as hetero-chitooligosaccharides, aminoethyl chitooligosaccharides, chitin derivatives, 
chitosan trimer oligomers and carboxylated chitooligosaccharides have been reported as potent ACE 
inhibitors. They are briefly discussed below as well as summarized in Table 2. 
Hong et al. [61] studied ACE inhibitory activity of different COS and identified that chitosan trimer 
is more effective in lowering blood pressure compared to other oligomers. Specifically, the trimer has 
a lower IC50 value (0.9 µ M) than most of the other molecular weight COS. In addition, Park et al. [73] 
reported  the  ACE  inhibitory  activities  of  different  molecular  weight  COS  or  hetero-COS.  ACE 
inhibitory activity of hetero-COS was dependent on the degree of deacetylation of chitosan. They have 
tested nine kinds of hetero-COS derivatives; prepared by 90%, 75% and 50% N-deacetylated of crab 
chitin with 40% NaOH solution and then each chitosan in to hetero-COS derivatives with relatively 
high molecular masses (5,000–10,000 Dalton), medium molecular masses (1,000–5,000 Dalton) and 
low molecular masses (below 1,000 Dalton) by ultrafiltration membrane bioreactor system. Among 
these hetero-COS, 50% deacetylated and medium molecular weight (1,000–5,000 Dalton) hetero-COS 
has exhibited the highest ACE inhibitory activity with the IC50 value of 1.22 mg/mL (Table 2.) and the 
inhibition pattern is competitive according to the Lineweaver-Burk plots. These findings suggested 
that  molecular  weight  and  degree  of  deacetylation  of  COS  are  important  factors  for  the  ACE  
inhibitory activity. 
Table 2. ACE inhibitory COS derived from marine resources: derivatives and IC50 values. 
COS derivative  IC50  Ref. 
Chitosan trimer  0.9 µ M  [61] 
Chitosan oligosaccharides  1.22 mg/mL  [73] 
Chitin derivatives 
AEC    0.064 µ M  [74] 
AEC 50  0.038 µ M  [74] 
AEC 90  0.103 µ M  [74] 
Aminoethyl-COS (AE-COS)  0.80 µ g/mL  [75] 
Captopril
a  0.1 µ M  [74] 
a positive control 
To develop ACE inhibitory chitin derivatives, chitin with different degrees of deacetylation have 
been  chemically  modified  by  grafting  2-chloroethylamino  hydrochloride  on  to  chitin  at  the  C-6 
position  [74].  Among  three  chitin  derivatives,  such  as  aminoethyl-chitin  with  10%  deacetylation 
(AEC),  aminoethyl-chitin  with  50%  deacetylation  (AEC50),  and  aminoethyl  chitin  with  90% 
deacetylation  (AEC90),  the  strongest  ACE  inhibitor  is  aminoethyl-chitin  with  50%  deacetylation  
(IC50 value, 0.038 µ M) and the inhibition is competitive. Captopril was used as the positive control 
(IC50 value, 0.1 µ M) in this study. Moreover, in vivo studies have shown that it effectively decreased 
the systolic blood pressure of spontaneously hypertensive rats in a dose-dependent manner. When 
comparing with the IC50 values of previous studies, these three water-soluble chitin derivatives have 
superior ACE inhibitory activity than that of chitosan oligosaccharide derivatives and captopril [74]. 
Furthermore, the structural properties of chitosan also can be improved by chemical modification to 
obtain higher active COS derivatives. For example, aminoethyl-COS were synthesized by grafting Mar. Drugs 2010, 8                             
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aminoethyl  functional  group  to  improve  its  ACE  inhibitory  activity  [75].  Hydroxyl  groups  of  the 
pyranose ring structure at different positions are different chemical attractions and hydroxyl group in 
the C-6 position was successfully replaced by the aminoethyl group because the structure of COS was 
maintained due to the C-6 hydroxyl group, which shows the highest reactivity for aminoethylation. 
Here, another advantage they acquired is that the aminoethyl COS derivatives are easily soluble in water. 
According to Ngo et al. [75], ACE inhibitory activity of aminoethyl-COS (AE-COS) has increased more 
than that of original COS. At the 2.5 µ g/mL concentration, COS and aminoethyl-COS exhibited ACE 
inhibitory  activities  of  18.6%  and  89.3%  respectively.  Further,  a  marked  dose-dependent  inhibitory 
effect has been reported in both COS and aminoethyl-COS treatment groups. 
Similarly, Huang et al. [76] have modified COS by carboxylation with –COCH2CH2COO
- groups 
to obtain specific structural features similar to captopril. ACE inhibitory activity of carboxylated COS 
enhances its activity with increased substitution degree and competitive inhibition has been observed. 
Further, improvement in ACE inhibitory activity of carboxylated-COS compared to COS might be due 
to the electrostatic interactions between positively charged sites of enzymatic and negatively charged 
carboxyl groups similar to captopril. 
In addition to the ACE, it has shown that renin also plays a vital role in the renin-angiotensin 
system. Renin (or angiotensinogenase), is a rate-limiting enzyme in the renin-angiotensin system. It 
cleaves plasma angiotensinogen to angiotensin-I, which is further converted by ACE to angiotensin-II. 
Therefore, the inhibition of renin activity is also an attractive target in hypertension therapy. Park et al. 
[77]  reported  that  COS  have  greater  potential  to  inhibit  renin  activity.  According  to  them,  90% 
deacetylated  and  medium  molecular  weight  (1,000–5,000  Dalton)  COS  has  the  strongest  renin 
inhibition  (IC50  value,  0.51  mg/mL)  and  act  as  a  competitive  inhibitor.  Collectively,  it  can  be 
suggested that COS derivatives are potent drug candidates for treat hypertension and their therapeutic 
role in pharmaceutical industry are assured. 
2.3. Phlorotannins 
Phlorotannins are phenolic compounds formed by the polymerization of phloroglucinol or defined 
as 1,3,5-trihydroxybenzene monomer units and biosynthesized through the acetate-malonate pathway. 
They  are  highly  hydrophilic  components  with  a  wide  range  of  molecular  sizes  ranging  between  
126–650,000 Dalton [78]. Marine brown algae and red algae accumulate a variety of phloroglucinol-
based polyphenols, as phlorotannins of low, intermediate and high molecular weight containing both 
phenyl and phenoxy units [79,80]. Among marine algae, Ecklonia cava; an edible brown algae is a rich 
source  of  phlorotannins  than  others  [81].  In  addition  to  E.  cava,  other  marine  algae  such  as  
E. stolonifera, Hizikia fusiforme, Eisenia bicyclis, and Eisenia arborea have been reported for various 
phlorotannins  [81].  Phlorotannins  have  several  health  beneficial  biological  activities  including, 
antioxidant [82], anti-HIV [83], antiproliferative [84], anti-inflammatory [85], radioprotective [86], 
antidiabetic [87], anti-Alzheimer’s disease (acetyl cholinesterase and butyryl cholinesterase inhibitory) [88], 
antimicrobial [89] and antihypertensive or ACE inhibitory activities (Table 3.). 
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Table  3.  ACE  inhibitory  phlorotannins  derived  from  marine  resources: 
phlorotannin/fraction and IC50 value. 
Phlorotannin/fraction  IC50  Ref. 
Phlorofucofuroeckol A  12.74 µ M  [89] 
Flavourzyme digest fraction of E. cava  0.3 µ g/mL  [91] 
Methanolic extract of A. flabelliformis  13.8 µ g/mL  [92] 
Captopril
a  0.05 µ g/mL  [91] 
a positive control 
 
The  ACE  inhibitory  activity  of  ten  Korean  seaweeds  including,  five  Phaeophyta  (E.  cava,  
E. stolonifera, Pelvetia siliqousa, H. fusiforme, and Undaria pinnatifida), four Rhodophyta (Gigartina 
tenella,  Gelidium  amansii,  Chondria  crassicaulis,  and  Porphyra  tenera),  and  one  Chlorophyta 
(Capsosiphon fulvescens) have screened by Jung et al. [90]. The ethanol extracts of E. stolonifera,  
E. cava, P. siliquosa, U. pinnatifida, and G. tenella exhibited significant inhibitory properties against 
ACE at more than 50% inhibition at a concentration of 163.93 µ g/mL. Moreover, they have found that 
phlorotannins such as eckol, phlorofucofuroeckol A, and dieckol, which derived from E. stolonifera 
have shown considerable inhibitory activity against ACE. Among them, phlorofucofuroeckol A is the 
strongest ACE inhibitor with an IC50 value of 12.74 µ M. Although current knowledge of relationship 
between the structure and activity of the active phlorotannins is limited, a closed ring dibenzo-1,4-dioxin 
moiety may be crucial to the above ACE inhibitory effect. In addition, the ACE inhibitory activity may 
depend on the degree of polymerization of phlorotannin derivatives. 
Polyphenolic compounds inhibit ACE activity through sequestration of the enzyme metal factor, 
Zn
2+ ion [91]. Therefore, it has been assumed that phlorotannins might form a complex associated with 
proteins  or  glycoproteins  to  inhibit  the  ACE  activity.  Athukorala  &  Jeon  [92]  have  reported  that 
flavourzyme enzymatic digest of E. cava, which contains high content of phlorotannins, is a potent 
ACE inhibitor, exhibited an IC50 of 0.3 µ g/ml and captopril, a commercial antihypertensive exhibited 
an  IC50  of  0.05  µ g/mL.  They  have  hydrolyzed  seven  marine  brown  algal  species  (E.  cava,  Ishige 
okamurae, Sargassum fulvellum, Sargassum horneri, Sargassum coreanum, Sargassum thunbergii, and 
Scytosiphon lomentaria) and analyzed for ACE inhibitory activities. Most of the above algal species 
showed potent ACE inhibitory activities however, E. cava is the most potent ACE inhibitor among 
them due to its rich content of phlorotannins. 
Furthermore, among twenty-six marine red algae, an aqueous extracts at 20 ° C of Lomentaria catenata 
and  Lithophyllum  okamurae  have  reported  for  potent  ACE  inhibitory  activity  with  IC50  values  
of  12.21  µ g/mL  and  13.78  µ g/mL,  respectively  [93].  From  the  methanol  extracts  at  20  ° C,  
Ahnfeltiopsis flabelliformis possessed the highest ACE inhibitory activity (IC50, 13.8 µ g/mL). 
Marine-derived phlorotannins are valuable bioactive compounds and could be introduced for the 
preparation of novel pharmaceuticals as well as functional foods, and their selection is also a good 
approach for the treatment or prevention of hypertension. Mar. Drugs 2010, 8                             
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3. Conclusions 
Recently, much attention has been paid by consumers towards natural bioactive compounds as 
functional  ingredients  and  hence  it  can  be  suggested  that,  marine-derived  ACE  inhibitors  are 
alternative tools that can contribute to consumer’s well-being, by being a part of novel nutraceuticals 
or  pharmaceuticals  replacing  synthetic  drugs.  Food  bioactive  compounds  are  often  effective  in 
promoting health and lead to the reduction of disease risk. Especially, bioactive compounds derived 
from marine organisms have served as a rich source of health-promoting components. Among them, 
bioactive  peptides,  chito-oligosaccharides,  and  phlorotannins  are  rich  sources  of  natural  health 
enhancers and this fact implies their potential as a functional ingredient in future nutraceutical and 
pharmaceutical products. According to presented data, it seems that most IC50 values of COS are lower 
than peptides and phlorotannins, when comparing the ACE inhibitory activity of these marine-derived 
ACE inhibitors. Until now, most of these ACE inhibitory activities have been observed in vitro or in 
mouse  model  systems.  Therefore,  further  research  studies  are  needed in  order  to  investigate  their 
activity in human subjects. In conclusion, it can be suggested that marine-derived ACE inhibitors such 
as bioactive peptides, chitooligosaccharides, and phlorotannins are potential therapeutic candidates for 
prevent hypertension and their involvement in the future pharmaceuticals are promising. 
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